Under construction – not a live service
Sign in
Taking people in NetherlandsPhase 1/2

Testing dendritic cell therapy in adults with type 1 diabetes

Tests immune-calming dendritic cell treatment in adults with type 1 diabetes.

Key facts

Who runs it
Academisch Ziekenhuis Leiden
Where
Leiden and Rotterdam, NetherlandsSee the 2 sites
Registry title
Tolerogenic dendritic cell therapy in type 1 diabetes; a phase 1b safety and immunological effecitivity study
Status
Recruiting
Phase
Phase 1/2
People taking part
10 people, planned
Started
2 Dec 2024
Expected to end
1 May 2028
Type of study
Interventional
Record updated
24 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 1 diabetes to test the safety of a tolerogenic dendritic cell therapy and how it affects the immune system.

Age
18 to 64 years
Sex
Men and women can join.

Main reasons for not taking part

  • Healthy volunteers cannot join.

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 64 years old?

Where in Netherlands

  • Academisch Ziekenhuis LeidenLeiden, NetherlandsTaking people
  • Diabeter Nederland B.V.Rotterdam, NetherlandsTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Testing dendritic cell therapy in adults with type 1 diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Fit questions
Built from 2023-508558-25-01, who can take part
Record updated
24 March 2026